Article Details

Real-world adverse event analysis based on the FAERS and JADER databases from 2013 to 2025

Retrieved on: 2025-10-10 17:59:42

Tags for this article:

Click the tags to see associated articles and topics

Real-world adverse event analysis based on the FAERS and JADER databases from 2013 to 2025. View article details on hiswai:

Excerpt

Obinutuzumab is the first glycosylated type II anti-CD20 monoclonal antibody for the treatment of lymphocytic leukemia and follicular lymphoma. This ...

Article found on: journals.plos.org

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo